A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15786 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Alexander Böhner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Thalidomide, Eczema. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase‐4. Patients and Methods A phase IIb randomized, double‐blind, placebo‐controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32. The primary endpoint was the number of patients achieving an improvement in Physician's Global Assessment (PGA) by two or more points or an absolute PGA of 0 or 1 at week 16. Secondary endpoints included changes in skin physiology, life quality, or dermato‐pathology.
Results
33 patients were enrolled, of whom 31 were randomized to apremilast (n = 15) or placebo (n = 16). 1/15 (6.7%) patients in the apremilast group and 4/16 (25.0%) in the placebo group reached the primary endpoint (p = 0.369). There was no difference between placebo and apremilast with regard to all secondary endpoints at week 16 and week 32. The safety profile was in accordance with the known safety profile of apremilast.
Conclusion
Phosphodiesterase‐4 inhibition by apremilast showed no beneficial effects for the treatment of NE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
- Dermazentrum, Freiburg, Germany.
- Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany.
- Division of Dermatology and Venereology, Department of Medicine Solna, and Center for molecular medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Dermatology and Allergy, LMU Hospital, Munich, Germany.
ORCID-Profile: Alexander Böhner, Peter Seiringer, Felix Lauffer
Zitieren
APA
Böhner, A., Seiringer, P., Kleeberger, V., Rogner, D., Oesterlin, C., Biedermann, T., Eyerich, K., & Lauffer, F. (2025). A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15786
Vancouver
Böhner A, Seiringer P, Kleeberger V, Rogner D, Oesterlin C, Biedermann T, et al. A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15786
BibTeX
@article{Bhner2025,
author = {Böhner, Alexander and Seiringer, Peter and Kleeberger, Viktoria and Rogner, Danielle and Oesterlin, Christian and Biedermann, Tilo and Eyerich, Kilian and Lauffer, Felix},
title = {A phase IIb single‐center study to assess the efficacy of apremilast for the treatment of nummular eczema},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15786}
}
EUVIMED